Patents by Inventor Alfred P. Spada

Alfred P. Spada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190022043
    Abstract: Provided herein are methods and compositions for treatment of an elevated MELD score or Child-Pugh score or their components by administering a of a caspase inhibitor alone or in combination with current treatments for liver disease.
    Type: Application
    Filed: December 30, 2016
    Publication date: January 24, 2019
    Inventor: Alfred P. Spada
  • Publication number: 20170100448
    Abstract: Provided herein are methods and compositions for treatment of a portal hypertension and cirrhosis by administering a of a caspase inhibitor alone or in combination with current treatments for portal hypertension. Also provided are methods and compositions for reducing the progression of the clinical complications associated with portal hypertension by administering the caspase inhibitors described herein.
    Type: Application
    Filed: May 11, 2015
    Publication date: April 13, 2017
    Inventor: Alfred P. SPADA
  • Publication number: 20160213736
    Abstract: Provided herein are methods and compositions for treatment of a portal hypertension and cirrhosis by administering a of a caspase inhibitor alone or in combination with current treatments for portal hypertension. Also provided are methods and compositions for reducing the progression of the clinical complications associated with portal hypertension by administering the caspase inhibitors described herein.
    Type: Application
    Filed: April 7, 2016
    Publication date: July 28, 2016
    Inventor: Alfred P. SPADA
  • Publication number: 20110212056
    Abstract: Provided herein are methods for treatment of a liver disease by administering a combination of a matrix metalloproteinase inhibitor and a caspase inhibitor. Also provided are methods for reducing liver damage associated with a liver disease by administering the MMP and caspase inhibitors described herein. Further provided are methods for lowering an elevated level of liver enzymes.
    Type: Application
    Filed: May 9, 2011
    Publication date: September 1, 2011
    Inventor: Alfred P. Spada
  • Publication number: 20100190688
    Abstract: Compounds, compositions and methods for treatment of hyperproliferative diseases, such as cancer are provided.
    Type: Application
    Filed: July 12, 2005
    Publication date: July 29, 2010
    Inventors: Bin Chao, Thomas L. Deckwerth, Paul S. Furth, Steven D. Linton, Alfred P. Spada, Brett R. Ullman, Michael I. Weinhouse
  • Patent number: 7612075
    Abstract: This invention is directed to oxoazaheterocycyl compounds which inhibit Factor Xa, to oxoazaheterocycyl compounds which inhibit both Factor Xa and Factor IIa, to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds, to a method of directly inhibiting Factor Xa and to a method of simultaneously directly inhibiting Factor Xa and Factor IIa.
    Type: Grant
    Filed: July 25, 2003
    Date of Patent: November 3, 2009
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: William R. Ewing, Michael R. Becker, Yong Mi Choi-Sledeski, Heinz W. Pauls, Wei He, Stephen M. Condon, Roderick S. Davis, Barbara A. Hanney, Alfred P. Spada, Christopher J. Burns, John Z. Jiang, Michael R. Myers, Wan F. Lau, Aiwen Li, Gregory B. Poli, Mark A. Bobko, Robert L. Morris, Joseph M. Karpinski, Timothy F. Gallagher, Kent W. Neuenschwander, Robert D. Groneberg, Jean-Francois Sabuco
  • Patent number: 7550597
    Abstract: This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor tyrosine kinase and/or Lck tyrosine kinase, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.
    Type: Grant
    Filed: January 25, 2005
    Date of Patent: June 23, 2009
    Assignee: Aventis Pharmaceuticals, Inc.
    Inventors: Michael R. Myers, Alfred P. Spada, Paul E. Persons, Martin P. Maguire
  • Publication number: 20080207569
    Abstract: Provided herein are methods for treatment of a liver disease by administering a matrix metalloproteinase inhibitor. Also provided are methods for reducing liver damage associated with a liver disease by administering the matrix metalloproteinase inhibitor described herein. Further provided are methods for lowering an elevated level of liver enzymes by administering the matrix metalloproteinase inhibitor.
    Type: Application
    Filed: February 28, 2008
    Publication date: August 28, 2008
    Inventor: Alfred P. Spada
  • Publication number: 20080207605
    Abstract: Provided herein are methods for treatment of a liver disease by administering a combination of a matrix metalloproteinase inhibitor and a caspase inhibitor. Also provided are methods for reducing liver damage associated with a liver disease by administering the MMP and caspase inhibitors described herein. Further provided are methods for lowering an elevated level of liver enzymes.
    Type: Application
    Filed: February 28, 2008
    Publication date: August 28, 2008
    Inventor: Alfred P. Spada
  • Patent number: 6852712
    Abstract: This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56lck tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.
    Type: Grant
    Filed: February 4, 2003
    Date of Patent: February 8, 2005
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Michael R. Myers, Wei He, Alfred P. Spada, Martin P. Maguire
  • Patent number: 6846815
    Abstract: This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor tyrosine kinase and/or Lck tyrosine kinase, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.
    Type: Grant
    Filed: February 3, 2003
    Date of Patent: January 25, 2005
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Michael R. Myers, Alfred P. Spada, Paul E. Persons, Martin P. Maguire
  • Patent number: 6821962
    Abstract: This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56lck tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.
    Type: Grant
    Filed: February 6, 2003
    Date of Patent: November 23, 2004
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Michael R. Myers, Wei He, Alfred P. Spada, Martin P. Maguire
  • Publication number: 20040102450
    Abstract: This invention is directed to oxoazaheterocycyl compounds which inhibit Factor Xa, to oxoazaheterocycyl compounds which inhibit both Factor Xa and Factor IIa, to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds, to a method of directly inhibiting Factor Xa and to a method of simultaneously directly inhibiting Factor Xa and Factor IIa..
    Type: Application
    Filed: July 25, 2003
    Publication date: May 27, 2004
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: William R. Ewing, Michael R. Becker, Yong Mi Choi-Sledeski, Heinz W. Pauls, Wei He, Stephen M. Condon, Roderick S. Davis, Barbara A. Hanney, Alfred P. Spada, Christopher J. Burns, John Z. Jiang, Aiwen Li, Michael R. Myers, Wan F. Lau, Gregory B. Poli, Mark A. Bobko, Robert L. Morris, Joseph M. Karpinski, Timothy F. Gallagher, Kent W. Neuenschwander, Robert D. Groneberg, Jean-Francois Sabuco
  • Patent number: 6696434
    Abstract: This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56lck tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.
    Type: Grant
    Filed: December 12, 2002
    Date of Patent: February 24, 2004
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Michael R. Myers, Wei He, Alfred P. Spada, Martin P. Maguire
  • Publication number: 20040014774
    Abstract: This invention relates to the modulation and/or inhibition of cell signaling, cell proliferation, cell inflammatory response, the control of abnormal cell growth and cell reproduction. More specifically, this invention relates to the use of mono- and/or bicyclic aryl or heteroaryl quinazoline compounds in inhibiting cell proliferation, including compounds which are useful protein tyrosine kinase (PTK) inhibitors. The method of treating cell proliferation and/or differentiation or mediator release using said quinazoline compounds and their use in pharmaceutical compositions is described.
    Type: Application
    Filed: July 10, 2003
    Publication date: January 22, 2004
    Inventors: Michael R. Myers, Alfred P. Spada, Martin P. Maguire, Paul E. Persons, Asher Zilberstein, Chin-Yi Jenny Hsu, Susan E. Johnson
  • Patent number: 6645969
    Abstract: This invention relates to the modulation and/or inhibition of cell signaling, cell proliferation, cell inflammatory response, the control of abnormal cell growth and cell reproduction. More specifically, this invention relates to the use of mono- and/or bicyclic aryl or heteroaryl quinazoline compounds in inhibiting cell proliferation, including compounds which are useful protein tyrosine kinase (PTK) inhibitors. The method of treating cell proliferation and/or differentiation or mediator release using said quinazoline compounds and their use in pharmaceutical compositions is described.
    Type: Grant
    Filed: May 18, 1995
    Date of Patent: November 11, 2003
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Michael R. Myers, Alfred P. Spada, Martin P. Maguire, Paul E. Persons, Asher Zilberstein, Chin-Yi Jenny Hsu, Susan E. Johnson
  • Publication number: 20030176390
    Abstract: This invention is directed to methods of treating insulin resistance syndrome and diabetes in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound derived from adenosine and analogues thereof, or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable prodrug thereof, an N-oxide thereof, a hydrate thereof or a solvate thereof, or a pharmaceutical composition comprising such compound.
    Type: Application
    Filed: May 14, 2002
    Publication date: September 18, 2003
    Inventors: Andreas Herling, Gerhard Jaehne, Martin P. Maguire, Alfred P. Spada, Michael R. Myers, Yong Mi Choi-Sledeski, Heinz W. Pauls, William R. Ewing
  • Publication number: 20030144284
    Abstract: This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor tyrosine kinase and/or Lck tyrosine kinase, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.
    Type: Application
    Filed: February 3, 2003
    Publication date: July 31, 2003
    Inventors: Michael R. Myers, Alfred P. Spada, Paul E. Persons, Martin P. Maguire
  • Publication number: 20030139399
    Abstract: This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56lck tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.
    Type: Application
    Filed: February 4, 2003
    Publication date: July 24, 2003
    Inventors: Michael R. Myers, Wei He, Alfred P. Spada, Martin P. Maguire
  • Publication number: 20030139400
    Abstract: This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56lck tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.
    Type: Application
    Filed: February 6, 2003
    Publication date: July 24, 2003
    Inventors: Michael R. Myers, Wei He, Alfred P. Spada, Martin P. Maguire